<DOC>
	<DOCNO>NCT01882179</DOCNO>
	<brief_summary>Heart attack , myocardial infarct , major cause death disability UK . Immediate unblocking obstruct heart vessel balloon catheter implantation mesh scaffold ( stent ) heart center warrant patient . Morbidity mortality patient group relate infarct size . Therefore , need discover novel therapeutic agent reduce myocardial infarct size preserve contractile heart function . Large trial involve several thousand patient demonstrate survival benefit patient impaired heart function due heart attack , receive mineralo-corticoid receptor antagonist ( MRA , drug name : spironolactone ) . In trial patient receive drug late , 3-14 day heart attack . Our proposal investigate whether MRA therapy administer intravenously prior unblock occluded heart vessel , reduce infarct size prevent long term sequelae heart attack . 150 patient admit 4 tertiary care hospital ( Heart Hospital London , London Chest , Essex Cardiothoracic Center Leeds General Infirmary ) heart attack randomly assign receive MRA treatment placebo . The first dose MRA apply intravenously immediately catheter suite , even re-opening occlude vessel . From second day , patient prescribe oral MRA treatment , pill , total three month . Before hospital discharge three month , magnetic resonance image ( MRI ) heart accurately investigate evolution infarct ( scar ) size contractile heart function compare group patient receive MRA drug versus placebo control group . Of note , patient ejection fraction &lt; 40 % AND sign heart failure OR diabetes go open label eplerenone accord current guideline , instead study drug . This study give first evidence , early MRA treatment improve heart function use early possible treatment patient heart attack .</brief_summary>
	<brief_title>Early Mineralocorticoid Receptor Antagonist Treatment Reduce Myocardial Infarct Size</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Reperfusion Injury</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Canrenoic Acid</mesh_term>
	<mesh_term>Mineralocorticoids</mesh_term>
	<criteria>Inclusion criterion entry trial Patients &gt; 18 year Patients present acute STEMI ( assess 12 lead ECG ; ST segment elevation ≥2 mm ( 0.2 mV ) 2 contiguous precordial lead ≥1mm ( 0.1mm ) 2 adjacent limb lead ) . Presentation within 12 hour symptom onset Inclusion criterion randomization ( assessed catheter laboratory ) Angiographically prove proximal occlusion ( TIMI 0 ) major coronary vessel ( LAD , LCX , RCA ) . Normal potassium ( &lt; 5.0 mmol/l ) Patients known LVEF ≤40 % Participation another trial Cardiogenic shock ( positive shock index OR need catecholamine support OR systolic blood pressure &lt; 90 mmHg ) Killip class &gt; 2 Prior myocardial infarction Known compromise renal function ( eGFR &lt; 30 ml/min/1.73 m2 ) potassium &gt; 5.0 mmol/l Current treatment mineralocorticoid receptor antagonists Pregnant lactate female Allergies IMP excipients Known contraindication cardiac magnetic resonance imaging ( MRI ) significant claustrophobia , severe allergy gadolinium chelate contrast , , presence MRI contraindicate implanted device ( eg , pacemaker , implanted cardiac defibrillator , cardiac resynchronization therapy device , cochlear implant ) , imbed metal object ( eg , shrapnel ) , contraindication cardiac MRI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Reperfusion injury</keyword>
	<keyword>myocardial infarct size</keyword>
	<keyword>MRI</keyword>
	<keyword>spironolactone</keyword>
</DOC>